Beyond Weight Loss: Effects of Semaglutide on Knee Pain, Physical Function, and Thigh Skeletal Muscle Volume in Obesity-Associated Knee Osteoarthritis.
5 affiliations
- 1Department of Orthopaedics, Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India.
- 2Department of Orthopaedics, Arunai Medical College, Tiruvannamalai, Tamil Nadu, India.
- 3Department of Orthopaedics, AIIMS, Bathinda, Punjab, India.
- 4Department of Orthopaedics, 21 September University for Medical and Applied Sciences, Sanaa, Yemen.
- 5Department of Naturopathy and Yoga, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India.
Abstract
Obesity is an important modifiable risk factor for knee osteoarthritis, contributing to pain, functional limitation, and systemic inflammation. Semaglutide may provide benefits beyond weight reduction, but its effects on clinical and functional outcomes in obesity-associated knee osteoarthritis remain insufficiently characterized. Against this background, this study sought to evaluate the effects of 6-month semaglutide treatment on weight, knee pain, physical function, thigh skeletal muscle volume, and inflammatory markers in patients with obesity-associated knee osteoarthritis. This prospective, observational, single-arm study included 75 patients with obesity-associated knee osteoarthritis who received semaglutide and were followed for 6 months. Changes in weight, body mass index (BMI), knee pain assessed by the Visual Analogue Scale (VAS), physical function assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), thigh skeletal muscle volume, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated. At the 6-month follow-up, body weight decreased from 101.23 ± 15.45 to 91.47 ± 9.67 kg (mean change -9.76 kg), while BMI decreased from 34.49 ± 3.67 to 31.89 ± 5.78 kg/m2 (-2.60 kg/ m2; both P < 0.001). VAS pain scores decreased from 6.90 ± 2.10 to 4.89 ± 0.73 (-2.01; P < 0.001), and WOMAC scores improved from 59.67 ± 6.47 to 44.60 ± 6.12 (-15.07; P < 0.001). Thigh skeletal muscle volume increased from 10.6 ± 2.3 to 11.1 ± 1.8 L (+0.50 L; P < 0.001). CRP decreased from 6.14 ± 0.73 to 3.91 ± 2.08 mg/L, while ESR decreased from 27.51 ± 3.32 to 19.64 ± 4.37 mm/h. 6 months of semaglutide treatment was associated with substantial weight loss and significant improvements in knee pain and physical function, accompanied by reductions in systemic inflammatory markers. These findings suggest potential benefits of semaglutide beyond weight reduction in obesity-associated knee osteoarthritis. Larger controlled studies with longer follow-up are warranted.
Related
- Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP
- Comparative effectiveness of exercise and self-management interventions delivered through different modes of digital support on pain and patient-reported physical function in people with knee osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials
- Long-term effects of the 50+ in motion intervention on physical function and healthcare utilization in older adults with and without osteoarthritis.
- Effects of Chondroitin Sulfate on Joint Symptoms and Physical Function in Adults with Mild Knee Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial
- Effects of Heat-Conduction Dry Needling on Pain and Physical Function in Early-to-Mid-Stage Knee Osteoarthritis: A Randomized Controlled Trial with 12-Month Follow-Up
BibTeX
@article{kumar2026beyond,
title = {{Beyond Weight Loss: Effects of Semaglutide on Knee Pain, Physical Function, and Thigh Skeletal Muscle Volume in Obesity-Associated Knee Osteoarthritis.}},
author = {Bodla Arvind Kumar and Nithin Sundaresan and Anuragdeep Syal and Mohammed Saleh AlSaifi and B Gokula Krishnan and B Mohanakrishnan},
journal = {Journal of orthopaedic case reports},
year = {2026},
month = nov,
doi = {10.13107/jocr.2026.v16.i11.8546},
url = {https://europepmc.org/article/MED/42997011},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Beyond Weight Loss: Effects of Semaglutide on Knee Pain, Physical Function, and Thigh Skeletal Muscle Volume in Obesity-Associated Knee Osteoarthritis.
AU - Bodla Arvind Kumar
AU - Nithin Sundaresan
AU - Anuragdeep Syal
AU - Mohammed Saleh AlSaifi
AU - B Gokula Krishnan
AU - B Mohanakrishnan
PY - 2026
DA - 2026/11/01
JO - Journal of orthopaedic case reports
DO - 10.13107/jocr.2026.v16.i11.8546
UR - https://europepmc.org/article/MED/42997011
AB - Obesity is an important modifiable risk factor for knee osteoarthritis, contributing to pain, functional limitation, and systemic inflammation. Semaglutide may provide benefits beyond weight reduction, but its effects on clinical and functional outcomes in obesity-associated knee osteoarthritis remain insufficiently characterized. Against this background, this study sought to evaluate the effects of 6-month semaglutide treatment on weight, knee pain, physical function, thigh skeletal muscle volume, and inflammatory markers in patients with obesity-associated knee osteoarthritis. This prospective, observational, single-arm study included 75 patients with obesity-associated knee osteoarthritis who received semaglutide and were followed for 6 months. Changes in weight, body mass index (BMI), knee pain assessed by the Visual Analogue Scale (VAS), physical function assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), thigh skeletal muscle volume, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were evaluated. At the 6-month follow-up, body weight decreased from 101.23 ± 15.45 to 91.47 ± 9.67 kg (mean change -9.76 kg), while BMI decreased from 34.49 ± 3.67 to 31.89 ± 5.78 kg/m2 (-2.60 kg/ m2; both P < 0.001). VAS pain scores decreased from 6.90 ± 2.10 to 4.89 ± 0.73 (-2.01; P < 0.001), and WOMAC scores improved from 59.67 ± 6.47 to 44.60 ± 6.12 (-15.07; P < 0.001). Thigh skeletal muscle volume increased from 10.6 ± 2.3 to 11.1 ± 1.8 L (+0.50 L; P < 0.001). CRP decreased from 6.14 ± 0.73 to 3.91 ± 2.08 mg/L, while ESR decreased from 27.51 ± 3.32 to 19.64 ± 4.37 mm/h. 6 months of semaglutide treatment was associated with substantial weight loss and significant improvements in knee pain and physical function, accompanied by reductions in systemic inflammatory markers. These findings suggest potential benefits of semaglutide beyond weight reduction in obesity-associated knee osteoarthritis. Larger controlled studies with longer follow-up are warranted.
SN - 2250-0685
SN - 2321-3817
ER -